Alkermes (NASDAQ: ALKS), a biopharmaceutical company that specializes in extended-release drug delivery technology, reported third-quarter results on Nov. 2 and provided investors with an update on its pipeline. Let's dig in to see what happened with the company during the period.Image source: Getty Images.Continue reading